The global melanoma cancer market is anticipated to grow at a CAGR of around 12.3% during the forecast period (2021-2027). The factor propelling the growth of the market include the rise in the number of FDA approvals for melanoma cancer drugs/systems produced by key market players. For instance, in July 2021, Genentech, a subsidiary of F. Hoffmann-La Roche Ltd, got the approval for Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib). These drugs are used for the treatment of BRAF V600 mutation-positive advanced melanoma. The FDA approval is supported by results from the Phase 3 IMspire150 clinical trial done on peoples who suffered from advanced melanoma and previously untreated BRAF V600 mutation. The approval will support Roche to build a strong market for the Tecentriq/Cotellic combo.
To Request a Sample of our Report on Melanoma Cancer Market: https://www.omrglobal.com/request-sample/melanoma-cancer-market
Moreover, in May 2020, SciBase, announced that it has received approval from the FDA for Nevisense 3.0, the third generation of their Nevisense system for early melanoma detection. Nevisence is an AI-based point-of-care system that is used for the non-invasive evaluation of irregular moles. Through this approval for the system to detect early melanoma cancer will support the company to expand its marketing and sales activities in the market. Thus, these approvals by FDA will impact positively the growth of the melanoma cancer market during the forecast period.
(Get 15% Discount on Buying this Report)
A full Report of Melanoma Cancer Market is Available at: https://www.omrglobal.com/industry-reports/melanoma-cancer-market
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Diagnosis
- By Therapy
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape- Bristol-Myers Squibb Co., GlaxoSmithKline plc, AstraZeneca PLC, Amgen Inc, Novartis AG, Abbott Laboratories, Johnson & Johnson Services, Inc., and others.
Global Melanoma Cancer Market Segmentation
By Diagnosis
- Biopsy
- Computed Tomography (CAT) Scan
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET) Scan
By Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Radiation Therapy
Regional Analysis
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Rest of The World
- Latin America
- Middle East & Africa
Company Profiles
- Abbott Laboratories
- Ab Sciences
- AbbVie Inc.
- Amgen, Inc.
- AstraZeneca plc
- Bristol-Myers Squibb Co.
- Castle Biosciences, Inc.
- Celgene Corp.
- Chinook Therapeutics, Inc.
- Daiichi Sankyo Co., Ltd.
- ENB Therapeutics
- Eisai Co Ltd.
- F. Hoffman-La Roche Ltd.
- GlaxoSmithKline PLC
- Incyte Corp.
- Iovance Biotherapeutics Inc.
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Novartis AG
- Pierre Fabre S. A.
- SciBase AB
Reasons to Buy From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/melanoma-cancer-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
